A distinct subset of FcγRI-expressing Th1 cells exert antibody-mediated cytotoxic activity
Diana Rasoulouniriana, … , Peleg Rider, Yaron Carmi
Diana Rasoulouniriana, … , Peleg Rider, Yaron Carmi
Published August 26, 2019
Citation Information: J Clin Invest. 2019;129(10):4151-4164. https://doi.org/10.1172/JCI127590.
View: Text | PDF
Research Article Immunology

A distinct subset of FcγRI-expressing Th1 cells exert antibody-mediated cytotoxic activity

Abstract

While a high frequency of Th1 cells in tumors is associated with improved cancer prognosis, this benefit has been attributed mainly to support of cytotoxic activity of CD8+ T cells. By attempting to potentiate antibody-driven immunity, we found a remarkable synergy between CD4+ T cells and tumor-binding antibodies. This surprising synergy was mediated by a small subset of tumor-infiltrating CD4+ T cells that express the high-affinity Fcγ receptor for IgG (FcγRI) in both mouse and human patients. These cells efficiently lyse tumor cells coated with antibodies through concomitant crosslinking of their T cell receptor (TCR) and FcγRI. By expressing FcγRI and its signaling chain in conventional CD4+ T cells, we successfully employed this mechanism to treat established solid cancers. Overall, this discovery sheds new light on the biology of this T cell subset, their function during tumor immunity, and the means to utilize their unique killing signals in immunotherapy.

Authors

Diana Rasoulouniriana, Nadine Santana-Magal, Amit Gutwillig, Leen Farhat-Younis, Yariv Wine, Corey Saperia, Lior Tal, Haim Gutman, Alexander Tsivian, Ronen Brenner, Eiman Abu Bandora, Nathan E. Reticker-Flynn, Peleg Rider, Yaron Carmi

×

Figure 1

Adoptive transfer of CD4+ T cells with tumor-binding antibodies induces direct killing of tumor cells.

Options: View larger image (or click on image) Download as PowerPoint
Adoptive transfer of CD4+ T cells with tumor-binding antibodies induces ...
(A) Illustration of experimental outline. (B) B16F10 tumor size (mm2) in WT mice following injection of CD8+ T cells isolated from day 7 tumor-bearing mice with or without antibodies against TRP-1 and DC stimuli (n = 4). (C) B16F10 tumor size (mm2) in WT mice following injection of CD4+ T cells isolated from day 7 tumor-bearing mice with or without antibodies against TRP-1 and DC stimuli (n = 4). The same control groups, PBS and TNF-α+CD40L+αTRP-1, were used in both B and C. (D) B16F10 tumor size (mm2) following adoptive transfer of CD4+ T clones, with or without DC stimuli and antibodies against TRP-1 and ovalbumin (n = 4). Results are from 1 representative experiment out of at least 3 performed. Statistical significance was calculated using 2-way ANOVA with post hoc Tukey’s test. ***P < 0.001; ****P < 0.0001. P < 0.05 was considered significant.